The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).
 
Brandon David Bernard
No Relationships to Disclose
 
Laurence Albiges
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Sanofi
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Sabina Signoretti
No Relationships to Disclose
 
Jesse Novak
No Relationships to Disclose
 
Michelle S. Hirsch
No Relationships to Disclose
 
Christophe Massard
No Relationships to Disclose
 
Yohann Loriot
No Relationships to Disclose
 
Elie Fadel
No Relationships to Disclose
 
Suzanne Chartier
No Relationships to Disclose
 
Vincent de Montpreville
No Relationships to Disclose
 
Karim Fizazi
Honoraria - Astellas Pharma; Janssen; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; Bayer; Curevac; Dendreon; Ipsen; Janssen Oncology; Novartis; Orion; Sanofi; Takeda
Travel, Accommodations, Expenses - Amgen
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Julien Adam
Consulting or Advisory Role - Roche/Genentech